Economy News

 

Johnson-And-Johnson, Subsidiaries Settle Case Over Prescription Drugs

Johnson-And-Johnson, Subsidiaries Settle Case Over Prescription Drugs

(Washington, DC) -- Johnson-and-Johnson and subsidiaries will pay more than $2.2 billion in penalties over problems with three prescription drugs. In a news conference, Attorney General Eric Holder said the drugs were never proven as safe and effective.

The prescription drugs are Risperdal, Invega and Natrecor.

Holder said Johnson-and-Johnson and subsidiaries also offered kickbacks to pharmacists to sell the drugs. Holder called the actions "shameful" and said they violated the trust of patients.

He said the Justice Department will "hold accountable any corporation that breaks the law and enriches its bottom line at the expense of the American people."

 

More Articles